Base-Date AMP and Inflation Rebates: When a Drug’s Pricing History Is Reset

Base date AMP fraud reduces Medicaid inflation rebates by falsely resetting the historical price used to measure a drug’s price increases. The drug has years of sales behind it, but the rebate calculation treats it as new. Earlier price increases disappear from the comparison, and the manufacturer keeps money owed to state Medicaid programs and the taxpayers who fund them. If you work in government pricing, product data or finance, you may know exactly when the history changed, who approved the change and what the company had already been told.

What Base-Date AMP Means for Medicaid Rebates

Base-date AMP is the historical average manufacturer price used to calculate a drug’s Medicaid inflation rebate. The calculation compares current AMP with that earlier price adjusted for inflation. An artificially high baseline can shrink the additional rebate owed on later sales.

The Medicaid Drug Rebate Program requires participating manufacturers to pay quarterly rebates to state Medicaid programs. The inflation component sits on top of the basic rebate and recaptures price growth beyond the consumer price index. The comparison follows each dosage form and strength. A manufacturer’s current price, historical baseline and the state’s reimbursed units all affect the bill.

For retail-channel drugs, AMP measures prices paid to the manufacturer by wholesalers for drugs distributed to retail community pharmacies, and by those pharmacies buying directly. The calculation applies specific exclusions, including customary prompt-pay discounts to wholesalers and qualifying service fees.

The Centers for Medicare & Medicaid Services rule on market dates and product reporting explains an important distinction inside the pricing system. Base-date AMP is product information that stays with the drug throughout its history. Current pricing information changes from period to period. In the Medicaid Drug Programs system, many baseline values come from the manufacturer’s reported base-quarter prices. Moving an old drug’s baseline forward can change every later comparison even when the current-quarter price is reported correctly.

Base Date AMP Reset After Drug Acquisition

A base date AMP reset after drug acquisition can remove price increases that occurred under the previous owner. The agency says the product’s market date follows its first sale by any manufacturer. Purchasing an existing drug does not restart that history.

The distinction reaches the product master. A different manufacturer or National Drug Code can identify a new commercial arrangement while the drug, dosage form and strength retain their earlier market date. Introducing a new package size also leaves the product’s market date in place. The date a buyer first sold its own inventory may come much later than the date the drug entered the market.

The 2024 rule uses first actual sale for new products while preserving correctly reported dates under earlier guidance. An acquisition still carries the previous manufacturer’s history with it.

That is why the acquisition file matters. The buyer needs the original product’s history and baseline information, including records that predate its ownership. The agency specifically recognized that some acquirers had treated the purchase date as the market date and might lack the earlier pricing records. A spreadsheet beginning on the acquisition date can leave out the very increases the inflation rebate is meant to capture.

The Quarter and the Rebate Cap Matter

The applicable base quarter depends on the drug’s category and first marketing date.

Since 2024 the stakes are higher. The American Rescue Plan Act removed the cap that had limited total Medicaid rebates to 100% of AMP. That change applies to periods beginning January 1, 2024. A rebate can now exceed the drug’s average manufacturer price. For a product with substantial accumulated price increases, the historical baseline can determine whether Medicaid receives more back than that average price.

Medicaid and Medicare Inflation Rebates Use Different Histories

Medicaid and Medicare inflation rebates use different benchmarks and periods. Medicare Part B uses average sales price, while Part D has its own inflation-rebate benchmark period. For an insider working across programs, the same product can appear in several reporting systems without the same price measure or baseline applying to all of them.

Acthar’s Earlier Price Increases Disappeared From the Calculation

Mallinckrodt’s Acthar case concerned an old drug reported as newly marketed after substantial price increases. In its March 2022 settlement announcement, the Justice Department alleged that Mallinckrodt and its predecessor, Questcor, used a 2013 starting point based on Food and Drug Administration approval of a new use in 2010.

Acthar had been marketed long before 1990. According to the government, Questcor had raised its price by more than $20,000 per unit before the reported reset. Using the later baseline allegedly kept those earlier increases out of the inflation rebate. The sales history continued. The rebate calculation started over.

According to the government, the Centers for Medicare & Medicaid Services warned Mallinckrodt repeatedly that it could not ignore the earlier increases. The whistleblower’s amended complaint describes what allegedly happened when finance calculated the exposure:

The allegation puts the company’s own calculation beside its response to the result. That is information someone inside finance can see even when the public sees only a drug price.

Mallinckrodt admitted that Acthar was not a new drug in 2013, had Food and Drug Administration approval and marketing before 1990, and agreed to correct its base-date AMP. Approximately $234.7 million of the settlement addressed the rebate allegations. Whistleblowers brought the cases, and the Justice Department announced approximately $24.7 million for the whistleblower in the rebate case from the federal recovery.

Nostrum Kept the Approval and Argued for a New Drug

Nostrum’s Nitro OS case connects an acquisition, a manufacturing pause and a relaunch to unpaid inflation rebates. The company’s admissions in the October 2023 settlement announcement explain what changed inside the bottle and what stayed the same.

Nostrum acquired Nitrofurantoin Oral Suspension and continued marketing it under its existing Food and Drug Administration approval. In 2018, it stopped manufacturing because lead levels did not comply with updated Food and Drug Administration guidance. It changed quantities of two inactive ingredients to reduce the lead and resumed manufacturing and marketing in August.

The company admitted that it added no ingredients and removed none. The active ingredients, dosage form and strength remained unchanged. It continued using the same approval, maintaining that no major changes had been made.

After the relaunch, Nostrum raised the price from about $475 to about $2,392 per bottle. The increase triggered substantially higher state Medicaid rebate invoices. Nostrum admitted that it did not pay the full invoiced amounts, despite learning why the bills had risen and receiving instructions from the Centers for Medicare & Medicaid Services to pay the higher amounts.

Nostrum then argued to the agency that the relaunched version was a new drug and should escape rebates based on the earlier version’s price. For FDA, the company maintained continuity with the approved product. For Medicaid, it sought a fresh pricing history.

The settlement resolved allegations of knowing rebate underpayments from October 2018 through March 2020. Nostrum and its chief executive agreed to a minimum of $3,825,000, potentially rising to $50 million if financial conditions were met. The contrast with Acthar is useful: one dispute followed approval of a new use, the other a change in inactive-ingredient quantities. Both concerned whether the government would still receive rebates reflecting the drug’s earlier prices.

Can an Inactive Ingredient Change Create a New Drug Base Date AMP?

An inactive ingredient change alone does not create a new drug base date AMP. The Centers for Medicare & Medicaid Services ties the market date to the drug’s approval, dosage form and strength. Its market-date explanation says that a drug under the same approved application cannot establish a new market date unless it has a new dosage form or strength.

Nostrum shows why the actual product history matters. The company described its relaunch as a reformulation, but admitted continuity in its approval, active ingredients, dosage form and strength. The before-and-after formulation and the representations to FDA and CMS supplied the comparison.

Line extensions raise another question. Under the Medicaid line-extension rule, changes in release mechanism, dosage form, strength, administration route or ingredients can constitute a new formulation. For covered line extensions of single-source or innovator multiple-source drugs whose original product is an oral solid dosage form, the rebate calculation can carry forward the original drug’s inflation exposure. The manufacturer owes the higher of the ordinary calculation or the alternative calculation tied to the original product.

A new use alone does not make a new formulation. Product category, market date and line-extension treatment each answer a different part of the rebate calculation. A new-product label in a commercial system settles none of them.

Why the Launch Price Belongs in the Story

Inflation rebates measure growth from a benchmark established for the product. The price at which a newly marketed drug starts therefore matters alongside every later increase.

The Congressional Budget Office’s January 2022 analysis of prescription drug spending observed that Medicaid’s inflation rebate may have contributed to higher launch prices while also dampening later price growth. That incentive explains why an old drug’s accumulated history is valuable to a manufacturer seeking a reset. The allegations in Acthar and Nitro OS concern the attempt to leave that history behind.

What Evidence Is Needed to Prove Fraud?

The evidence connects the drug’s actual history, the baseline reported to CMS, the resulting rebate shortfall and the company’s knowledge. Product-master history, acquisition records, pricing calculations, state invoices and internal communications can supply different parts of that connection. Connecting them is the work we do with you.

The reporting controls leave their own trail. The manufacturer reporting provisions in the 2016 Code of Federal Regulations required certification by the chief executive, chief financial officer, an equivalent officer or a direct delegate. They also required supporting records, including calculation assumptions and revised submissions. In the newer market-date rule, the Centers for Medicare & Medicaid Services also explains that manufacturers remain responsible for data accuracy when the agency enters a requested change on their behalf.

The distinction between a correction entered and a correction certified matters. The agency says uncertified changes do not become final or flow into quarterly rebate calculations. Its misclassification process covers both incorrect product reporting and payment at a level inconsistent with correctly reported information. The earlier quarters remain part of the account.

Product-data comparisons have exposed actual reporting problems. In a September 2020 review, the Department of Health and Human Services Office of Inspector General found inaccurate product data after comparing manufacturer submissions with labels, package inserts and other public information. For a base-date case, those comparisons belong alongside the company’s earlier submissions and its response to warnings.

The Acthar complaint alleged that a supervisor restricted discussion of the calculated liability. Nostrum admitted receiving government instructions to pay the larger rebate invoices. Those are the kinds of connections that make an insider’s knowledge valuable: what the company understood, what it reported and what it paid.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

When You Know Why the Baseline Changed

If you know why an established drug acquired a new pricing history, talk to our whistleblower experts about the baseline and the rebates it changed. We work with you to connect the product history, internal decisions and unpaid rebates into your strongest whistleblower case. We stay beside you throughout, and we bring in pharmaceutical pricing whistleblower lawyers who understand Medicaid rebate disputes.